CAMBRIDGE, Mass., Oct. 18, 2016 /PRNewswire/ -- Common Sensing, Inc. today announced it has kicked off the first clinical study of its Gocap™ real-time insulin dose monitoring solution at Joslin Diabetes Center in Boston with study partners Sanofi* and Dexcom.
More than 6 million insulin users in the United States administer insulin daily by injection. Maintaining a daily dosing regimen is a time-consuming burden for users, and clinicians have little insight into their patients' actual insulin use between office visits. As a result, clinicians cannot make data-driven decisions and more than 1/3rd of type 2 diabetic insulin users are non-adherent.  Each year, this costs an average of ~$2500 per user. 
The study will examine the use of disposable insulin pens with the Gocap™ smart cap and associated glycemic control. Both insulin pen use and continuous blood glucose response will be measured automatically around the clock for 125 participants, yielding valuable and actionable data. Study partners are Sanofi, who is providing funding, and Dexcom, who is providing continuous glucose monitoring wearable devices. Joslin endocrinologists and Hilary Ginsburg, R.N., Director of Clinical Research at Common Sensing, designed the study.
"Clinicians need to see their patients' glucose data in context with insulin use data," said Medha Munshi, M.D., Joslin endocrinologist and primary investigator for the study. "Being able to see missing doses, potential misuse, and signs of complications would give clinicians the ability to quickly work with patients to plan a course of action."
The Gocap™ is an insulin monitoring device that fits on existing disposable injectors, which are prescribed to a majority of insulin users in the United States and Europe. The Bluetooth-enabled cap automatically generates an insulin logbook that can be wirelessly shared with care providers and family. Users can visualize and share their data over the cloud and receive reminders and alerts from the accompanying Gocap™ App for Android and iOS smartphones.
"The team is excited by the enthusiastic response from both clinicians and insulin users who see Gocap as a powerful solution for improving the daily management of diabetes," said James White, president of Common Sensing. "Modern chronic disease management is broken. To fix it, we must connect and build trust between people and their healthcare: providers, medications, and devices. Gocap makes that possible for today's insulin users."
Common Sensing registered the device and mobile application with the FDA in July 2016 and is actively pursuing partnering, distribution, and study opportunities before launch.
For more information, contact:
 Chandran, Arthi, et al. "Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus." American health & drug benefits 8.3 (2015): 148.
 Kymes, S. M., et al. "Association among change in medical costs, level of comorbidity, and change in adherence behavior." The American journal of managed care 22.8 (2016): e295.
About Common Sensing
Common Sensing is a startup building the next generation of smart health technologies and services to reduce the burden of chronic disease on individuals and society. Founded in 2012, Common Sensing has assembled a team of talented designers and engineers to develop Gocap™, a smart cap to connect insulin pens to the cloud. The company prides itself in user-centered design and the development of patented sensor technologies. Using these technologies, Common Sensing markets services to both improve chronic disease outcomes and make everyday treatment more convenient. Based in Cambridge, MA, Common Sensing's investors include Waterline Ventures, Qualcomm Ventures, and Sanofi.
* The agreement is with Sanofi-Aventis Groupe.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/common-sensing-begins-study-with-cloud-based-insulin-monitoring-solution-to-address-5b-treatment-management-challenge-300344709.html
SOURCE Common Sensing